

a/b/h



103372632

SEP 12 AM 11:39

To the Director of the U.S. Patent and Trademark Office

Documents of the new address(es) below.

1. Name of conveying party(ies)

TransTech Pharma, Inc.

Additional name(s) of conveying party(ies) attached? Yes No

2. Name and address of receiving party(ies)

Name: Pfizer Inc

Internal Address: _____

Street Address: 150 East 42nd Street

City: New York

State: New York

Country: United States Zip: 10017

Additional name(s) & address(es) attached? Yes No

3. Nature of conveyance/Execution Date(s):

Execution Date(s) September 15, 2006

Assignment Merger

Security Agreement Change of Name

Joint Research Agreement

Government Interest Assignment

Executive Order 9424, Confirmatory License

Other Exclusive Patent Sublicense Confirmation

4. Application or patent number(s): This document is being filed together with a new application.

A. Patent Application No.(s)

PLEASE SEE ATTACHMENT A

B. Patent No.(s)

PLEASE SEE ATTACHMENT A

Additional numbers attached? Yes No

5. Name and address to whom correspondence concerning document should be mailed:

Name: Andrea E. Dorigo

Internal Address: Pfizer Inc

Street Address: 150 East 42nd Street

City: New York

State: New York Zip: 10017

Phone Number: _____

Fax Number: _____

Email Address: _____

6. Total number of applications and patents involved: 44

7. Total fee (37 CFR 1.21(h) & 3.41) \$1760.00

Authorized to be charged by credit card

Authorized to be charged to deposit account

Enclosed

None required (government interest not affecting title)

8. Payment Information

a. Credit Card Last 4 Numbers _____ Expiration Date _____

b. Deposit Account Number 16-1445

Authorized User Name Andrea E. Dorigo

9. Signature:

Andrea E. Dorigo Signature

2/19/07 Date

ANDREA E. DORIGO
Name of Person Signing

Total number of pages including cover sheet, attachments, and documents: 3

Documents to be recorded (including cover sheet) should be faxed to (571) 273-0140, or mailed to: Mail Stop Assignment Recordation Services, Director of the USPTO, P.O.Box 1450, Alexandria, V.A. 22313-1450

Application Licensed to TransTech Pharma, Inc. under
Exclusive License from Trustees of Columbia
University

Attachment A

App. No.
08/592,070
PCT/US97/00857
08/755,235
PCT/US97/21197
10/850,861
08/905,709
11/319,949
PCT/US98/16303
09/498,459
08/948,131
PCT/US98/21346
08/997,464
09/062,365
PCT/US99/08427
09/689,469
09/851,071
09/167,705
09/263,312
PCT/US99/23303
09/826,589
10/665,867
10/666,513
09/166,649
10/783,635
PCT/US99/23245
09/374,213
PCT/US00/22059
10/049,893
09/687,528
09/638,648
09/992,955
09/638,649
PCT/US04/014476
10/840,927
09/872,185
10/990,310
PCT/US04/028712
10/570,674
PCT/US04/036170
10/577,506
PCT/US04/036173
10/577,382
PCT/US06/010045
11/477,274

CONFIRMATION OF EXCLUSIVE PATENT SUBLICENSE

This Confirmation of Exclusive Patent Sublicense ("Confirmation") is given by Pfizer Inc., a Delaware corporation, located at 235 East 42nd Street, New York, New York 10017 ("Pfizer").

1. TransTech Pharma, Inc., a Delaware corporation, located at 4170 Mendenhall Oaks Parkway, High Point, North Carolina 27265 ("TransTech"), and Pfizer have executed a License and Research Agreement, dated as of September 15, 2006 (the "Patent Sublicense").

2. In the Patent Sublicense, TransTech has granted to Pfizer an exclusive sublicense to develop TTP4000 and TTP3000, and derivatives and/or variants thereof, and TTP488 and back-up compounds of TTP488 (collectively, "TransTech Molecules") into pharmaceutical or biological preparations containing TransTech Molecules, and to make and have made, use, sell, offer for sale, have sold and import TransTech Molecules and pharmaceutical or biological preparations containing TransTech Molecules under all patents and patent applications listed in Attachment A, to which TransTech is the exclusive licensee, pursuant to agreements ("Columbia agreements") by and among TransTech and the Trustees of Columbia University in the City of New York ("Columbia"), the Columbia Agreements being (a) a license agreement dated May 25, 2000, as amended on December 22, 2003, September 30, 2005, June 30, 2006, September 11, 2006 and September 14, 2006; (b) a research agreement dated May 25, 2000; and (c) a research agreement dated June 30, 2006.

3. This Confirmation is being delivered by Pfizer for the purpose of recording the Patent Sublicense with the U.S. Patent and Trademark Office ("PTO") and providing third parties (including subsequent purchasers or mortgagees) with notice of Pfizer's rights under the Patent Sublicense. For confidentiality reasons, Pfizer does not wish to record the Patent Sublicense in its entirety.

4. This Confirmation does not modify any of the terms of the Patent Sublicense and is expressly subject to its terms and conditions. The Patent Sublicense shall remain in full force and effect in accordance with its terms.

PFIZER INC.



Name: Peter C. Richardson

Title: Senior Vice President and
Associate General Counsel

PATENT

RECORDED: 02/12/2007

REEL: 018912 FRAME: 0021